A compound according to formula , or a salt thereof, wherein A represents a heteroaryl optionally substituted by at least one halogen, and B and C independently represent a radical selected from: a hydrogen, a C 1 -C 6 alkyl, a C 1 -C 6 alkoxy, and a group according to formula (II), wherein R 1 and R 2 represent, independently of each other, a radical selected from a hydrogen, a C 1 -C 3 alkyl, a C 1 -C 3 alkoxy, a group according to the formula -Y-[W]n-Z, wherein Y is a radical selected from O, N, S and C; W is a radical selected from C 1 -C 6 alkyl, C 1 -C 6 alkylene and C 2 -C 6 alkenyl; n is 0 or 1; Z represents a phenyl, a pyrrole or a naphthalene, aryl, an imidazole, naphthyl, or a phenanthrene optionally substituted by at least one radical selected from a C 1 -C 3 alkyl, a C 1 -C 3 alkoxy and a halogen wherein when C is hydrogen, methyl or methoxy, B is a group according to formula (II), and conversely when B is hydrogen, methyl or methoxy, C is a group according to formula (II), and when R 1 is hydrogen, C 1 -C 3 alkyl or C 1 -C 3 alkoxy, R 2 is the group -Y-[W]n-Z, and conversely when R 2 is hydrogen, C 1 -C 3 alkyl or C 1 -C 3 alkoxy, R 1 is the group -Y-[W]n-Z, for use in a method for treating HIV infection in a subject with HIV and/or for use in a method for treating HIV latency in latent HIV-infected cells in a subject with HIV. A represents a heteroaryl optionally substituted by at least one halogen, and B and C independently represent a radical selected from: a hydrogen, a C 1 -C 6 alkyl, a C 1 -C 6 alkoxy, and a group according to formula (II), wherein R 1 and R 2 represent, independently of each other, a radical selected from a hydrogen, a C 1 -C 3 alkyl, a C 1 -C 3 alkoxy, a group according to the formula -Y-[W]n-Z, wherein Y is a radical selected from O, N, S and C; W is a radical selected from C 1 -C 6 alkyl, C 1 -C 6 alkylene and C 2 -C 6 alkenyl; n is 0 or 1; Z represents a phenyl, a pyrrole or a naphthalene, aryl, an imidazole, naphthyl, or a phenanthrene optionally substituted by at least one radical selected from a C 1 -C 3 alkyl, a C 1 -C 3 alkoxy and a halogen wherein when C is hydrogen, methyl or methoxy, B is a group according to formula (II), and conversely when B is hydrogen, methyl or methoxy, C is a group according to formula (II), and when R 1 is hydrogen, C 1 -C 3 alkyl or C 1 -C 3 alkoxy, R 2 is the group -Y-[W]n-Z, and conversely when R 2 is hydrogen, C 1 -C 3 alkyl or C 1 -C 3 alkoxy, R 1 is the group -Y-[W]n-Z, for use in a method for treating HIV infection in a subject with HIV and/or for use in a method for treating HIV latency in latent HIV-infected cells in a subject with HIV. a hydrogen, a C 1 -C 6 alkyl, a C 1 -C 6 alkoxy, and a group according to formula (II), wherein R 1 and R 2 represent, independently of each other, a radical selected from a hydrogen, a C 1 -C 3 alkyl, a C 1 -C 3 alkoxy, a group according to the formula -Y-[W]n-Z, wherein Y is a radical selected from O, N, S and C; W is a radical selected from C 1 -C 6 alkyl, C 1 -C 6 alkylene and C 2 -C 6 alkenyl; n is 0 or 1; Z represents a phenyl, a pyrrole or a naphthalene, aryl, an imidazole, naphthyl, or a phenanthrene optionally substituted by at least one radical selected from a C 1 -C 3 alkyl, a C 1 -C 3 alkoxy and a halogen wherein when C is hydrogen, methyl or methoxy, B is a group according to formula (II), and conversely when B is hydrogen, methyl or methoxy, C is a group according to formula (II), and when R 1 is hydrogen, C 1 -C 3 alkyl or C 1 -C 3 alkoxy, R 2 is the group -Y-[W]n-Z, and conversely when R 2 is hydrogen, C 1 -C 3 alkyl or C 1 -C 3 alkoxy, R 1 is the group -Y-[W]n-Z, for use in a method for treating HIV infection in a subject with HIV and/or for use in a method for treating HIV latency in latent HIV-infected cells in a subject with HIV. <EOS>